Clinical trial · Interventional
Solid Tumors in RASopathies
Incidence and Molecular Pathogenesis of Solid Tumors in RASopathies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RASopathies are a group of syndromes, caused by variants of genes involved in the regulation of the Ras/MAP/ERK pathway. This intracellular transduction pathway profoundly affects embryogenic development, organogenesis, synaptic plasticity and neuronal growth. RASopathies are characterized by multi-organ involvement, growth delay, premature aging and haemato-oncological manifestations. Based on evidences provided by literature, cancer screening protocols are applied in some individuals affected by RASopathies, even though detailed information about prevalence and molecular pathogenesis of such tumors is still not clearly elucidate.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardio-Facio-Cutaneous Syndrome | — | UNRESOLVED | — |
| Costello Syndrome | — | UNRESOLVED | — |
| Noonan Syndrome | — | UNRESOLVED | — |
| RASopathy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Molecular characterization of solid tumor in RASopathies | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Case group
- description
- To report the prevalence of solid tumors in a monocentric cohort of individuals with RASopathies
- interventionNames
- Diagnostic Test: Molecular characterization of solid tumor in RASopathies
Primary outcomes (1)
- measure
- Prevalence of solid tumors in RASopathies
- timeFrame
- 5 years
- description
- To detect prevalence of solid tumors in monocentric cohort of RASopathies
Secondary outcomes (1)
- measure
- Molecular characterization of solid tumors in RASopathies
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Clinical and molecularly confirmed diagnosis of a RASopathy Exclusion Criteria: * Clinical diagnosis of RASopathy without molecular characterization
References
Publications (0)
Data not yet available